Skip to main content
Journal cover image

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Publication ,  Journal Article
Hernandez, AF; Green, JB; Janmohamed, S; D'Agostino, RB; Granger, CB; Jones, NP; Leiter, LA; Rosenberg, AE; Sigmon, KN; Somerville, MC ...
Published in: Lancet
October 27, 2018

BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30-50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. FINDINGS: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68-0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. INTERPRETATION: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. FUNDING: GlaxoSmithKline.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

October 27, 2018

Volume

392

Issue

10157

Start / End Page

1519 / 1529

Location

England

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Injections, Subcutaneous
  • Hypoglycemic Agents
  • Humans
  • Glucagon-Like Peptide 1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hernandez, A. F., Green, J. B., Janmohamed, S., D’Agostino, R. B., Granger, C. B., Jones, N. P., … Harmony Outcomes committees and investigators. (2018). Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, 392(10157), 1519–1529. https://doi.org/10.1016/S0140-6736(18)32261-X
Hernandez, Adrian F., Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino, Christopher B. Granger, Nigel P. Jones, Lawrence A. Leiter, et al. “Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.Lancet 392, no. 10157 (October 27, 2018): 1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X.
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519–29.
Hernandez, Adrian F., et al. “Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.Lancet, vol. 392, no. 10157, Oct. 2018, pp. 1519–29. Pubmed, doi:10.1016/S0140-6736(18)32261-X.
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519–1529.
Journal cover image

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

October 27, 2018

Volume

392

Issue

10157

Start / End Page

1519 / 1529

Location

England

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Injections, Subcutaneous
  • Hypoglycemic Agents
  • Humans
  • Glucagon-Like Peptide 1